|
|
|
| Protective effect of IL-1RA on airway inflammation and airway remodeling in COPD model rats |
| LIU Jing WEI Fengqin ZHAO Weiye LUAN Nianxu LIU Xuedong▲ |
| Department of Respiration, Qingdao Municipal Hospital, Shandong Province, Qingdao 266012, China |
|
|
|
Abstract Objective To investigate the protective effect of interleukin-1 receptor antagonist (IL-1RA) on airway inflammation and airway remodeling in rats with chronic obstructive pulmonary disease (COPD). Methods Thirty Wistar rats were induced by smoking and intratracheal injection of lipopolysaccharide (LPS). They were divided into control group, methylprednisolone treatment group and IL-1RA treatment group according to random number table method, with 10 rats in each group. Rats in each group were continuously intervened for 20 days starting on the 20th day. The control group was injected with 0.5 mg/(kg·d) saline, the methylprednisolone treatment group was injected with 0.5 mg/(kg·d) methylprednisolone, and the IL-1RA treatment group was subcutaneously injected with IL-lRA l00 pg per rat. The appearance of rats in each group was observed, blood gas was measured, lung histopathological examination was carried out, and mean alveolar number (MAN) and mean lining interval (MLI) were calculated. The content of High mobility group protein B1 (HMGB1) in bronchoalveolar lavage fluid (BALF) of rats in each group was detected by enzyme-linked immunosorbent assay, and the expression of HMGB1 in lung tissue of rats in each group was detected by Western blot. Results After treatment, there were significant differences in MAN and MLI among the three groups (P < 0.05). MAN in IL-1RA group was higher than that in methylprednisolone group and control group (P < 0.05), and MLI in IL-1RA group was significantly lower than that in methylprednisolone group and control group (P < 0.05). The expression of HMGB1 in BALF and lung tissue of three groups was significantly different (P < 0.05). The expression of HMGB1 in BALF of IL-1RA group was lower than that of methylprednisolone group and control group (P < 0.05), and the expression of HMGB1 in lung tissue was lower than that of methylprednisolone group and control group (P < 0.05). Conclusion IL-RA can reduce the expression of HMGB1 in lung tissue and alveoli of COPD rats, reduce airway inflammation, improve blood gas function and protect airway remodeling.
|
|
|
|
|
|
[1] Rabe KF，Watz H. Chronic obstructive pulmonary disease [J]. Lancet，2017，389（10 082）：1931-1940.
[2] Molimard M，Raherison C，Lignot S，et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling：real-life assessment of 2935 patients [J]. Eur Respir J，2017，49（2）：1 601 794.
[3] 满鑫，高燕鲁，俞晓滢.COPD气道重塑非炎症机制的研究进展[J].山东医药，2017，57（13）：110-112.
[4] Pauwels NS，Bracke KR，Dupont LL，et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD [J]. Eur Respir J，2011，38（5）：1019-1028.
[5] Pma C，Sethi S，Dawson M，et al. A randomised，placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease [J]. Respir Res，2017，18（1）：153.
[6] 侯嘉，马伟荣，刘洁，等.慢性阻塞性肺疾病患者肺组织和血清HMGB1的表达及与TNF-α和IL-1β的相关性[J].中国老年学杂志，2014（18）：5064-5066.
[7] 宋一平，崔德健，茅培英.慢性阻塞性肺病大鼠模型的建立及药物干预的影响[J].中华内科杂志，2000，39（8）：556-557.
[8] 刘成，胡俊锋.COPD急性加重危险因素的研究进展[J].国际呼吸杂志，2017，37（7）：520-526.
[9] Pera T，Zuidhof AB，Smit M，et al. Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease [J]. J Pharmacol Exp Ther，2014，349（2）：229-238.
[10] 周新.慢性阻塞性肺病急性加重的诊断与药物治疗进展[J].临床肺科杂志，2007，12（4）：319-320.
[11] 肖芹.纳洛酮辅助无创正压通气治疗对稳定期COPD患者肺功能、动脉血气指标及心率的影响[J].成都医学院学报，2018，13（5）：554-559.
[12] 李进勇，曾玮.沙美特罗氟替卡松对急性加重期COPD患者骨代谢以及气道重塑的影响分析[J].临床和实验医学杂志，2017，16（14）：1406-1410.
[13] 柯华，陈维永.吸入糖皮质激素对慢性阻塞性肺疾病患者肺癌发生风险影响的系统评价[J].成都医学院学报，2018，13（4）：467-472.
[14] 包明红，梅晓冬.慢性阻塞性肺疾病急性加重期联合吸入药物治疗的临床研究[J].临床肺科杂志，2011，16（7）：1018-1020.
[15] 孙惠萍，徐惠娟，戴加乐.糖皮质激素不同给药方式对急性加重期慢性阻塞性肺疾病治疗的有效性和安全性[J].中国医药导报，2016，13（1）：130-132.
[16] 于婧，袁雅冬.白介素1受体拮抗剂与呼吸系统疾病[J].国际呼吸杂志，2010，30（11）：697-704.
[17] Wahab F，Santos-Junior NN，de Almeida Rodrigues RP，et al. Interleukin-1 Receptor Antagonist Decreases Hypothalamic Oxidative Stress During Experimental Sepsis [J]. Mol Neurobiol，2016，53（6）：3992-3998.
[18] Jones RL，Noble PB，Elliot JG，et al. Airway remodelling in COPD：It′s not asthma! [J]. Respirology，2016，21（8）：1347-1356.
[19] 李红，吕志强，梁瑞韵.慢性阻塞性肺疾病合并心血管疾病的研究进展[J].临床肺科杂志，2017，22（4）：729-734.
[20] 贺建峰，姚旭升，杨静，等.基于关联规则算法的慢性阻塞性肺疾病及其协同发病分析[J].北京生物医学工程，2018，37（6）：618-623，630.
[21] Hou C，Kong J，Liang Y，et al. HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts [J]. Cell Mol Immunol，2015， 12（4）：409-423.
[22] Bellussi LM，Iosif C，Sarafoleanu C，et al. Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? [J]. J Biol Regul Homeost Agents，2013，27（3）：791-804.
[23] Huang KF，Huang WT，Lin KC，et al. Interleukin-1 receptor antagonist inhibits the release of glutamate，hydroxyl radicals，and prostaglandin E in the hypothalamus during pyrogen-induced fever in rabbits [J]. Eur J Pharmacol，2010，629（1）：125-131.
[24] 王志华，谢俊刚.慢性阻塞性肺疾病的表观遗传学机制研究进展[J].中华结核和呼吸杂志，2017，40（6）：472-474.
[25] 肖文香，程知音.噻托溴铵对慢性阻塞性肺疾病急性发作期患者血清炎性因子和血气分析指标的影响[J].中国医院用药评价与分析，2018，18（9）：1235-1237.
[26] 李进勇，曾玮.沙美特罗氟替卡松对急性加重期COPD患者骨代谢以及气道重塑的影响分析[J].临床和实验医学杂志，2017，16（14）：1406-1410. |
|
|
|
